Relevance of infection with human papillomavirus: The role of the p53 tumor suppressor protein and E6/E7 zinc finger proteins (Review)

Ruttkay-Nedecky,Branislav; Jimenez Jimenez,Ana  Maria; Nejdl,Lukas; Chudobova,Dagmar; Gumulec,Jaromir; Masarik,Michal; Adam,Vojtech; Kizek,Rene

doi:10.3892/ijo.2013.2105

Relevance of infection with human papillomavirus: The role of the p53 tumor suppressor protein and E6/E7 zinc finger proteins (Review)

Authors:
- Branislav Ruttkay-Nedecky
- Ana Maria Jimenez Jimenez
- Lukas Nejdl
- Dagmar Chudobova
- Jaromir Gumulec
- Michal Masarik
- Vojtech Adam
- Rene Kizek
View Affiliations

Affiliations: Department of Chemistry and Biochemistry, Faculty of Agronomy, Mendel University in Brno, CZ-613 00 Brno, Czech Republic, Central European Institute of Technology, Brno University of Technology, CZ-616 00 Brno, Czech Republic
Published online on: September 17, 2013 https://doi.org/10.3892/ijo.2013.2105
Pages: 1754-1762

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Human papillomaviruses (HPV) are small circular, double-stranded DNA viruses infecting epithelial tissues. HPV types can be classified both as high-risk or low-risk. Of the more than 120 different identified types of HPV, the majority are involved in infections of the genital tract, cancer of the cervix, vulva, vagina and penis, and of non-anogenital localizations, such as the head and neck areas. From the point of view of the infection, human papillomaviruses have developed several molecular mechanisms to enable infected cells to suppress apoptosis. This review provides a comprehensive and critical summary of the current literature that focuses on cervical carcinoma and cancer of the head and neck caused by HPV. In particular, we discuss HPV virology, the molecular mechanisms of carcinogenesis, the role of the tumor suppressor protein p53 and the E6/E7 zinc finger proteins. Classification of HPV according to diagnosis is also described.

View Figures

View References

1.	Stanley M: Pathology and epidemiology of HPV infection in females. Gynecol Oncol. 117:S5–S10. 2010. View Article : Google Scholar : PubMed/NCBI
2.	Lowy DR, Strickland JE and Yuspa SH: Efficient induction of papillomas by Harvey murine sarcoma-virus. Clin Res. 34:A7641986.
3.	Joh J, Jenson AB, Proctor M, et al: Molecular diagnosis of a laboratory mouse papillomavirus (MusPV). Exp Mol Pathol. 93:416–421. 2012. View Article : Google Scholar : PubMed/NCBI
4.	Mitsouras K, Faulhaber EA, Hui G, et al: Development of a PCR assay to detect papillomavirus infection in the snow leopard. BMC Vet Res. 7:1–11. 2011. View Article : Google Scholar : PubMed/NCBI
5.	Badulescu F, Crisan A, Badulescu A and Schenker M: Recent data about the role of human papillomavirus (HPV) in oncogenesis of head and neck cancer. Rom J Morphol Embryol. 51:437–440. 2010.PubMed/NCBI
6.	Fakhry C, Westra WH, Cmelak SLA, et al: Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst. 100:261–269. 2008. View Article : Google Scholar : PubMed/NCBI
7.	Syrjanen S: Human papillomavirus (HPV) in head and neck cancer. J Clin Virol. 32:S59–S66. 2005. View Article : Google Scholar : PubMed/NCBI
8.	Walden MJ and Aygun N: Head and neck cancer. Semin Roentgenol. 48:75–86. 2013. View Article : Google Scholar
9.	Forte T, Niu J, Lockwood GA and Bryant HE: Incidence trends in head and neck cancers and human papillomavirus (HPV)-associated oropharyngeal cancer in Canada, 1992–2009. Cancer Causes Control. 23:1343–1348. 2012.
10.	Axell T, Pindborg JJ, Smith CJ and van der Waal I: Oral white lesions with special reference to precancerous and tobacco related lesions: conclusions of an international symposium held in Uppsala, Sweden, May 18–21 1994. J Oral Pathol Med. 25:49–54. 1996.PubMed/NCBI
11.	Janicek MF and Averette HE: Cervical cancer: prevention, diagnosis, and therapeutics. CA Cancer J Clin. 51:92–114. 2001. View Article : Google Scholar : PubMed/NCBI
12.	Chen YC and Hunter DJ: Molecular epidemiology of cancer. CA Cancer J Clin. 55:45–54. 2005. View Article : Google Scholar
13.	De Villiers EM, Fauquet C, Broker TR, Bernard HU and zur Hausen H: Classification of papillomaviruses. Virology. 324:17–27. 2004.
14.	Bernard HU, Burk RD, Chen ZG, van Doorslaer K, zur Hausen H and de Villiers EM: Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology. 401:70–79. 2010. View Article : Google Scholar : PubMed/NCBI
15.	Doorbar J, Quint W, Banks L, et al: The biology and life-cycle of human papillomaviruses. Vaccine. 30:F55–F70. 2012. View Article : Google Scholar : PubMed/NCBI
16.	Chen RW, Aaltonen LM and Vaheri A: Human papillomavirus type 16 in head and neck carcinogenesis. Rev Med Virol. 15:351–363. 2005. View Article : Google Scholar : PubMed/NCBI
17.	Pfister H: HPV and skin neoplasia. Hautarzt. 59:26–30. 2008.(In German).
18.	Steben M and Duarte-Franco E: Human papillomavirus infection: epidemiology and pathophysiology. Gynecol Oncol. 107:S2–S5. 2007. View Article : Google Scholar : PubMed/NCBI
19.	Chang KC, Su IJ, Tsai ST, Shieh DB and Jin YT: Pathological features of betel quid-related oral epithelial lesions in Taiwan with special emphasis on the tumor progression and human papillomavirus association. Oncology. 63:362–369. 2002. View Article : Google Scholar
20.	Kero K, Rautava J, Syrjanen K, Grenman S and Syrjanen S: Oral mucosa as a reservoir of human papillomavirus: point prevalence, genotype distribution, and incident infections among males in a 7-year prospective study. Eur Urol. 62:1063–1070. 2012.
21.	Hong AM, Martin A, Armstrong BK, et al: Human papillomavirus modifies the prognostic significance of T stage and possibly N stage in tonsillar cancer. Ann Oncol. 24:215–219. 2013. View Article : Google Scholar : PubMed/NCBI
22.	Milano MT, Peterson CR, Zhang H, Singh DP and Chen Y: Second primary lung cancer after head and neck squamous cell cancer: population-based study of risk factors. Head Neck. 34:1782–1788. 2012. View Article : Google Scholar : PubMed/NCBI
23.	Ragin CCR and Taioli E: Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis. Int J Cancer. 121:1813–1820. 2007. View Article : Google Scholar : PubMed/NCBI
24.	Lin KY, Westra WH, Kashima HK, Mounts P and Wu TC: Coinfection of HPV-11 and HPV-16 in a case of laryngeal squamous papillomas with severe dysplasia. Laryngoscope. 107:942–947. 1997. View Article : Google Scholar : PubMed/NCBI
25.	Syrjanen KJ, Chang F and Syrjanen SM: HPV infections in etiology of benign and malignant sinonasal, bronchial and oesophageal squamous cell lesions. Eurogin 2000: 4th International Multidisciplinary Congress. Monsonego J: Medimond S R L: 40128 Bologna; pp. 169–179. 2000
26.	Hoffmann M, Klose N, Gottschlich S, et al: Detection of human papillomavirus DNA in benign and malignant sinonasal neoplasms. Cancer Lett. 239:64–70. 2006. View Article : Google Scholar : PubMed/NCBI
27.	Syrjanen S: Human papillomavirus infections and oral tumors. Med Microbiol Immunol. 192:123–128. 2003. View Article : Google Scholar : PubMed/NCBI
28.	Kashima HK, Kessis T, Hruban RH, Wu TC, Zinreich SJ and Shah KV: Human papilloma virus in sinonasal papillomas and squamous-cell carcinoma. Laryngoscope. 102:973–976. 1992. View Article : Google Scholar : PubMed/NCBI
29.	Mansell NJ and Bates GJ: The inverted Schneiderian papilloma: a review and literature report of 43 new cases. Rhinology. 38:97–101. 2000.PubMed/NCBI
30.	Zandberg DP, Bhargava R, Badin S and Cullen KJ: The role of human papillomavirus in nongenital cancers. CA Cancer J Clin. 63:57–81. 2013. View Article : Google Scholar : PubMed/NCBI
31.	Ustav M, Ustav E, Szymanski P and Stenlund A: Identification of the origin of replication of bovine papillomavirus and characterization of the viral origin recognition factor-E1. EMBO J. 10:4321–4329. 1991.PubMed/NCBI
32.	Baker CC, Phelps WC, Lindgren V, Braun MJ, Gonda MA and Howley PM: Structural and transcriptional analysis of human papillomavirus type-16 sequences in cervical-carcinoma cell-lines. J Virol. 61:962–971. 1987.PubMed/NCBI
33.	Bouvard V, Storey A, Pim D and Banks L: Characterization of the human papillomavirus E2 protein - evidence of transactivation and transrepression in cervical keratinocytes. EMBO J. 13:5451–5459. 1994.PubMed/NCBI
34.	Foguel D, Silva JL and de Prat-Gay G: Characterization of a partially folded monomer of the DNA-binding domain of human papillomavirus E2 protein obtained at high pressure. J Biol Chem. 273:9050–9057. 1998. View Article : Google Scholar : PubMed/NCBI
35.	Zur Hausen H: Cervical carcinoma and human papillomavirus: on the road to preventing a major human cancer. J Natl Cancer Inst. 93:252–253. 2001.
36.	Barbosa MS, Lowy DR and Schiller JT: Papillomavirus polypeptide-E6 and polypeptide-E7 are zinc-binding proteins. J Virol. 63:1404–1407. 1989.PubMed/NCBI
37.	Scheffner M, Werness BA, Huibregtse JM, Levine AJ and Howley PM: The E6 oncoprotein encoded by human papillomavirus type-16 and type-18 promotes the degradation of P53. Cell. 63:1129–1136. 1990. View Article : Google Scholar : PubMed/NCBI
38.	Vega-Pena A, Illades-Aguiar B, Flores-Alfaro E, Lopez-Bayghen E, Reyes-Maldonado E and Alarcon-Romero LD: Correlation between KI-67 and telomerase expression with in situ hybridization for high-risk human papillomavirus. Arch Biol Sci. 65:81–90. 2013. View Article : Google Scholar
39.	Li DS, Dong BL, Hu ZM, et al: A combined assay of hTERT and E6 oncoprotein to identify virus-infected keratinocytes with higher telomerase activity in human papillomaviruses 16 and 18-related bowenoid papulosis. Am J Dermatopathol. 34:813–817. 2012. View Article : Google Scholar
40.	Zhao YX, Qi L, Chen F, Zhao Y and Fan CH: Highly sensitive detection of telomerase activity in tumor cells by cascade isothermal signal amplification based on three-way junction and base-stacking hybridization. Biosens Bioelectron. 41:764–770. 2013. View Article : Google Scholar
41.	Wilting SM, Verlaat W, Jaspers A, et al: Methylation-mediated transcriptional repression of microRNAs during cervical carcinogenesis. Epigenetics. 8:220–228. 2013. View Article : Google Scholar : PubMed/NCBI
42.	Dayyani F, Etzel CJ, Liu M, Ho CH, Lippman SM and Tsao AS: Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC). Head Neck Oncol. 2:1–11. 2010. View Article : Google Scholar : PubMed/NCBI
43.	Dyson N, Howley PM, Munger K and Harlow E: The human papilloma virus-16 E7-oncoprotein is able to bind to the retinoblastoma gene-product. Science. 243:934–937. 1989. View Article : Google Scholar : PubMed/NCBI
44.	Strati K, Pitot HC and Lambert PF: Identification of biomarkers that distinguish human papillomavirus (HPV)-positive versus HPV-negative head and neck cancers in a mouse model. Proc Natl Acad Sci USA. 103:14152–14157. 2006. View Article : Google Scholar : PubMed/NCBI
45.	Smith EM, Pawlita M, Rubenstein LM, Haugen TH, Hamsikova E and Turek LP: Risk factors and survival by HPV-16 E6 and E7 antibody status in human papillomavirus positive head and neck cancer. Int J Cancer. 127:111–117. 2010. View Article : Google Scholar : PubMed/NCBI
46.	Doorbar J and Gallimore PH: Identification of proteins encoded by the L1 and L2 open reading frames of human papillomavirus 1a. J Virol. 61:2793–2799. 1987.PubMed/NCBI
47.	Rose BR, Thompson CH, Tattersall MH, O’Brien CJ and Cossart YE: Squamous carcinoma of the head and neck: molecular mechanisms and potential biomarkers. Aust N Z J Surg. 70:601–606. 2000. View Article : Google Scholar : PubMed/NCBI
48.	Wiest T, Schwarz E, Enders C, Flechtenmacher C and Bosch FX: Involvement of intact HPV16 E6/E7 gene expression in head and neck cancers with unaltered p53 status and perturbed pRb cell cycle control. Oncogene. 21:1510–1517. 2002. View Article : Google Scholar : PubMed/NCBI
49.	Bedell MA, Jones KH and Laimins LA: The E6-E7 region of human papillomavirus type-18 is sufficient for transformation of NIH-3T3 and RAT-1 cells. J Virol. 61:3635–3640. 1987.PubMed/NCBI
50.	Choo KB, Pan CC and Han SH: Integration of human papillomavirus type-16 into cellular DNA of cervical-carcinoma-preferential deletion of the E2 gene and invariable retention of the long control region and the E6/E7 open reading frames. Virology. 161:259–261. 1987. View Article : Google Scholar
51.	Huibregtse JM, Scheffner M and Howley PM: Cloning and expression of the cDNA for E6-AP, a protein that mediates the interaction of the human papillomavirus E6 oncoprotein with P53. Mol Cell Biol. 13:775–784. 1993.PubMed/NCBI
52.	Chellappan S, Kraus VB, Kroger B, et al: Adenovirus-E1A, simian virus-40 tumor-antigen, and human papillomavirus-E7 protein share the capacity to disrupt the interaction between transcription factor-E2F and the retinoblastoma gene-product. Proc Natl Acad Sci USA. 89:4549–4553. 1992. View Article : Google Scholar
53.	Cobrinik D, Dowdy SF, Hinds PW, Mittnacht S and Weinberg RA: The retinoblastoma protein and the regulation of cell cycling. Trends Biochem Sci. 17:312–315. 1992. View Article : Google Scholar : PubMed/NCBI
54.	Nevins JR: E2F - a link between the Rb tumor suppressor protein and viral oncoproteins. Science. 258:424–429. 1992. View Article : Google Scholar : PubMed/NCBI
55.	Gillison ML, Koch WM, Capone RB, et al: Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst. 92:709–720. 2000. View Article : Google Scholar : PubMed/NCBI
56.	May P and May E: Twenty years of p53 research: structural and functional aspects of the p53 protein. Oncogene. 18:7621–7636. 1999.PubMed/NCBI
57.	Yu ZK, Geyer RK and Maki CG: MDM2-dependent ubiquitination of nuclear and cytoplasmic P53. Oncogene. 19:5892–5897. 2000. View Article : Google Scholar : PubMed/NCBI
58.	Haupt Y, Maya R, Kazaz A and Oren M: Mdm2 promotes the rapid degradation of p53. Nature. 387:296–299. 1997. View Article : Google Scholar : PubMed/NCBI
59.	Huibregtse JM, Scheffner M and Howley PM: A cellular protein mediates association of P53 with the E6 oncoprotein of human papillomavirus type-16 or type-18. EMBO J. 10:4129–4135. 1991.PubMed/NCBI
60.	Chen JJ, Hong YH, Rustamzadeh E, Baleja JD and Androphy EJ: Identification of an alpha helical motif sufficient for association with papillomavirus E6. J Biol Chem. 273:13537–13544. 1998. View Article : Google Scholar : PubMed/NCBI
61.	Elston RC, Napthine S and Doorbar J: The identification of a conserved binding motif within human papillomavirus type 16 E6 binding peptides, E6AP and E6BP. J Gen Virol. 79:371–374. 1998.PubMed/NCBI
62.	Huibregtse JM, Scheffner M and Howley PM: Localization of the E6-AP regions that direct human papillomavirus E6 binding, association with P53, and ubiquitination of associated proteins. Mol Cell Biol. 13:4918–4927. 1993.PubMed/NCBI
63.	Yu Y, Yang AM, Hu SK, Zhang JH and Yan H: Significance of human papillomavirus 16/18 infection in association with p53 mutation in lung carcinomas. Clin Respir J. 7:27–33. 2013. View Article : Google Scholar : PubMed/NCBI
64.	Katori H, Nozawa A and Tsukuda M: Relationship between p21 and p53 expression, human papilloma virus infection and malignant transformation in sinonasal-inverted papilloma. Clin Oncol. 18:300–305. 2006. View Article : Google Scholar
65.	Fujita S, Senba M, Kumatori A, Hayashi T, Ikeda T and Toriyama K: Human papillomavirus infection in oral verrucous carcinoma: genotyping analysis and inverse correlation with p53 expression. Pathobiology. 75:257–264. 2008. View Article : Google Scholar
66.	Reschner A, Bontems S, Le Gac S, et al: Ruthenium oligonucleotides, targeting HPV16 E6 oncogene, inhibit the growth of cervical cancer cells under illumination by a mechanism involving p53. Gene Ther. 20:435–443. 2013. View Article : Google Scholar : PubMed/NCBI
67.	Togtema M, Pichardo S, Jackson R, Lambert PF, Curiel L and Zehbe I: Sonoporation delivery of monoclonal antibodies against human papillomavirus 16 E6 restores p53 expression in transformed cervical keratinocytes. PLoS One. 7:1–12. 2012. View Article : Google Scholar
68.	Habbous S, Pang V, Eng L, et al: p53 Arg72Pro polymorphism, HPV status and initiation, progression, and development of cervical cancer: a systematic review and meta-analysis. Clin Cancer Res. 18:6407–6415. 2012. View Article : Google Scholar : PubMed/NCBI
69.	Chen SP, Hsu NY, Wu JY, et al: Association of p53 codon 72 genotypes and clinical outcome in human papillomavirus-infected lung cancer patients. Ann Thorac Surg. 95:1196–1203. 2013. View Article : Google Scholar : PubMed/NCBI
70.	Grossman SR and Laimins LA: E6-protein of human papillomavirus type-18 binds zinc. Oncogene. 4:1089–1093. 1989.PubMed/NCBI
71.	Kanda T, Watanabe S, Zanma S, Sato H, Furuno A and Yoshiike K: Human papillomavirus type-16 E6 proteins with glycine substitution for cysteine in the metal-binding motif. Virology. 185:536–543. 1991. View Article : Google Scholar : PubMed/NCBI
72.	Beerheide W, Bernard HU, Tan YJ, Ganesan A, Rice WG and Ting AE: Potential drugs against cervical cancer: zinc-ejecting inhibitors of the human papillomavirus type 16 E6 oncoprotein. J Natl Cancer Inst. 91:1211–1220. 1999. View Article : Google Scholar : PubMed/NCBI
73.	Chan SY, Delius H, Halpern AL and Bernard HU: Analysis of genomic sequences of 95 papillomavirus types - uniting typing, phylogeny, and taxonomy. J Virol. 69:3074–3083. 1995.PubMed/NCBI
74.	Ullman CG, Haris PI, Galloway DA, Emery VC and Perkins SJ: Predicted alpha-helix/beta-sheet secondary structures for the zinc-binding motifs of human papillomavirus E7 and E6 proteins by consensus prediction averaging and spectroscopic studies of E7. Biochem J. 319:229–239. 1996.
75.	Griffin H, Elston R, Jackson D, et al: Inhibition of papillomavirus protein function in cervical cancer cells by intrabody targeting. J Mol Biol. 355:360–378. 2006. View Article : Google Scholar : PubMed/NCBI
76.	Zimmermann H, Degenkolbe R, Bernard HU and O’Connor MJ: The human papillomavirus type 16 E6 oncoprotein can down-regulate p53 activity by targeting the transcriptional coactivator CBP/p300. J Virol. 73:6209–6219. 1999.PubMed/NCBI
77.	Jong JE, Jeong KW, Shin H, Hwang LR, Lee D and Seo T: Human papillomavirus type 16 E6 protein inhibits DNA fragmentation via interaction with DNA fragmentation factor 40. Cancer Lett. 324:109–117. 2012. View Article : Google Scholar : PubMed/NCBI
78.	Mavromatis KO, Jones DL, Mukherjee R, Yee C, Grace M and Munger K: The carboxyl-terminal zinc-binding domain of the human papillomavirus E7 protein can be functionally replaced by the homologous sequences of the E6 protein. Virus Res. 52:109–118. 1997. View Article : Google Scholar
79.	Wayengera M: Zinc finger arrays binding human papillomavirus types 16 and 18 genomic DNA: precursors of gene-therapeutics for in-situ reversal of associated cervical neoplasia. Theor Biol Med Model. 9:1–13. 2012. View Article : Google Scholar
80.	Cannavo I, Benchetrit M, Loubatier C, Michel G, Lemichez E and Giordanengo V: Characterization of a cluster of oncogenic mutations in E6 of a human papillomavirus 83 variant isolated from a high-grade squamous intraepithelial lesion. J Gen Virol. 92:2428–2436. 2011. View Article : Google Scholar : PubMed/NCBI
81.	Avvakumov N, Torchia J and Mymryk JS: Interaction of the HPV E7 proteins with the pCAF acetyltransferase. Oncogene. 22:3833–3841. 2003. View Article : Google Scholar : PubMed/NCBI
82.	Mino T, Mori T, Aoyama Y and Sera T: Cell-permeable artificial zinc-finger proteins as potent antiviral drugs for human papillomaviruses. Arch Virol. 153:1291–1298. 2008. View Article : Google Scholar : PubMed/NCBI
83.	Olthof NC, Straetmans J, Snoeck R, Ramaekers FCS, Kremer B and Speel EJM: Next-generation treatment strategies for human papillomavirus-related head and neck squamous cell carcinoma: where do we go? Rev Med Virol. 22:88–105. 2012. View Article : Google Scholar : PubMed/NCBI
84.	Garcia-Vallve S, Alonso A and Bravo IG: Papillomaviruses: different genes have different histories. Trends Microbiol. 13:514–521. 2005. View Article : Google Scholar : PubMed/NCBI
85.	Van Doorslaer K, Sidi A, Zanier K, et al: Identification of unusual E6 and E7 proteins within avian papillomaviruses: cellular localization, biophysical characterization, and phylogenetic analysis. J Virol. 83:8759–8770. 2009.
86.	Cole ST and Danos O: Nucleotide-sequence and comparative-analysis of the human papillomavirus type 18 genome. Phylogeny of papillomaviruses and repeated structure of the E6 and E7 gene products. J Mol Biol. 193:599–608. 1987. View Article : Google Scholar : PubMed/NCBI
87.	Gammoh N, Grm HS, Massimi P and Banks L: Regulation of human papillomavirus type 16 E7 activity through direct protein interaction with the E2 transcriptional activator. J Virol. 80:1787–1797. 2006. View Article : Google Scholar : PubMed/NCBI
88.	Ruttkay-Nedecky B, Nejdl L, Gumulec J, et al: The role of metallothionein in oxidative stress. Int J Mol Sci. 14:6044–6066. 2013. View Article : Google Scholar : PubMed/NCBI
89.	Krizkova S, Ryvolova M, Hrabeta J, et al: Metallothioneins and zinc in cancer diagnosis and therapy. Drug Metab Rev. 44:287–301. 2012. View Article : Google Scholar : PubMed/NCBI
90.	Eckschlager T, Adam V, Hrabeta J, Figova K and Kizek R: Metallothioneins and cancer. Curr Protein Pept Sci. 10:360–375. 2009. View Article : Google Scholar : PubMed/NCBI
91.	Krizkova S, Fabrik I, Adam V, Hrabeta J, Eckschlager T and Kizek R: Metallothionein - a promising tool for cancer diagnostics. Bratisl Lek Listy. 110:93–97. 2009.PubMed/NCBI
92.	Babula P, Masarik M, Adam V, et al: Mammalians’ metallothioneins and their properties and functions. Metallomics. 4:739–750. 2012.
93.	Krejcova L, Fabrik I, Hynek D, et al: Metallothionein electrochemically determined using Brdicka reaction as a promising blood marker of head and neck malignant tumours. Int J Electrochem Sci. 7:1767–1784. 2012.
94.	Sochor J, Hynek D, Krejcova L, et al: Study of metallothionein role in spinocellular carcinoma tissues of head and neck tumours using Brdicka reaction. Int J Electrochem Sci. 7:2136–2152. 2012.
95.	Masarik M, Cernei N, Majzlik P, et al: Level of metallothionein, glutathione and heat-stable proteins in tumours from patients with head and neck cancer. Int J Mol Med. 26:S462010.
96.	Dutsch-Wicherek M, Lazar A, Tomaszewska R, Kazmierczak W and Wicherek L: Analysis of metallothionein and vimentin immunoreactivity in pharyngeal squamous cell carcinoma and its microenvironment. Cell Tissue Res. 352:341–349. 2013. View Article : Google Scholar : PubMed/NCBI
97.	Jayasurya A, Bay BH, Yap WM, Tan NG and Tan BKH: Proliferative potential in nasopharyngeal carcinoma: correlations with metallothionein expression and tissue zinc levels. Carcinogenesis. 21:1809–1812. 2000. View Article : Google Scholar : PubMed/NCBI
98.	Dutsch-Wicherek M, Popiela TJ, Klimek M, et al: Metallothionein stroma reaction in tumor adjacent healthy tissue in head and neck squamous cell carcinoma and breast adenocarcinoma. Neuroendocrinol Lett. 26:567–574. 2005.PubMed/NCBI
99.	Babula P, Kohoutkova V, Opatrilova R, Dankova I, Masarik M and Kizek R: Pharmaceutical importance of zinc and metallothionein in cell signalling. Chim Oggi-Chem Today. 28:18–21. 2010.
100.	Gumulec J, Masarik M, Krizkova S, et al: Insight to physiology and pathology of zinc(II) ions and their actions in breast and prostate carcinoma. Curr Med Chem. 18:5041–5051. 2011. View Article : Google Scholar : PubMed/NCBI
101.	Meplan C, Richard MJ and Hainaut P: Metalloregulation of the tumor suppressor protein p53: zinc mediates the renaturation of p53 after exposure to metal chelators in vitro and in intact cells. Oncogene. 19:5227–5236. 2000. View Article : Google Scholar : PubMed/NCBI
102.	Hainaut P and Mann K: Zinc binding and redox control of p53 structure and function. Antioxid Redox Signal. 3:611–623. 2001. View Article : Google Scholar : PubMed/NCBI
103.	Pintus SS, Ivanisenko NV, Demenkov PS, et al: The substitutions G245C and G245D in the Zn²⁺-binding pocket of the p53 protein result in differences of conformational flexibility of the DNA-binding domain. J Biomol Struct Dyn. 31:78–86. 2013.PubMed/NCBI
104.	Tohyama C, Suzuki JS, Hemelraad J, Nishimura N and Nishimura H: Induction of metallothionein and its localization in the nucleus of rat hepatocytes after partial-hepatectomy. Hepatology. 18:1193–1201. 1993. View Article : Google Scholar : PubMed/NCBI
105.	Tsujikawa K, Imai T, Kakutani M, et al: Localization of metallothionein in nuclei of growing primary cultured adult-rat hepatocytes. FEBS Lett. 283:239–242. 1991. View Article : Google Scholar : PubMed/NCBI
106.	Nartey NO, Banerjee D and Cherian MG: Immunohistochemical localization of metallothionein in cell-nucleus and cytoplasm of fetal human-liver and kidney and its changes during development. Pathology. 19:233–238. 1987. View Article : Google Scholar : PubMed/NCBI
107.	Banerjee D, Onosaka S and Cherian MG: Immunohistochemical localization of metallothionein in cell-nucleus and cytoplasm of rat-liver and kidney. Toxicology. 24:95–105. 1982. View Article : Google Scholar : PubMed/NCBI
108.	Tohno Y, Tohno S, Minami T, et al: Bindings of metallothionein to supranucleosomal fibers in mouse pancreatic nuclei after induction by 4-aminopyrazolo [3,4-d] pyrimidine. Cell Mol Biol. 42:1121–1127. 1996.PubMed/NCBI
109.	Sunderman FW, GrbacIvankovic S, Plowman MR and Davis M: Zn²⁺-induction of metallothionein in myotomal cell nuclei during somitogenesis of Xenopus laevis. Mol Reprod Dev. 43:444–451. 1996.
110.	Bernard X, Robinson P, Nomine Y, et al: Proteasomal degradation of p53 by human papillomavirus E6 oncoprotein relies on the structural integrity of p53 core domain. PLoS One. 6:1–10. 2011. View Article : Google Scholar : PubMed/NCBI